Idorsia AG is grappling with significant financial challenges, highlighted by a 34% drop in share price to EUR 1.508, despite the recent approval of its antihypertensive drug Aprocitentan in the USA. The company is focusing on cost-cutting and launching new products to improve its financial situation, with quarterly figures due in May expected to indicate the effectiveness of this strategy. The short-term outlook for Idorsia shares remains uncertain, hinging on the company's ability to stabilize its financing in the long run.
